Omnipaque™ (iohexol)

The only low-osmolar contrast medium (LOCM) listed in the WHO (World Health Organisation) essential drug list1 and used in over 600 million procedures2

Fast Facts

  • Indicated for intravenous intra-arterial body cavity intrathecal & gastrointestinal studies5

  • IV

    98% of paediatric patients undergoing abdominal CT, many of whom were under the age of five, drank the required volume of diluted Omnipaque3

  • Every 2 seconds, 3 procedures utilise Omnipaque1

  • The only low osmolar contrast agent on the WHO essential drug list1

  • search

    Omnipaque is approved for use in both adults and children9

  • Omnipaque has been used in over 690 million procedures to date2

  • +PLUSPAK™ efficiency helps in reducing costs & environmental impact, and hazards6-8

  • preview-eyeball

    No LOCM was better tolerated than Omnipaque in a prospective randomized study of 8,931 CT patients4

References:
1. WHO Model List of Essential Medicines, 20th List, August 2017
2. Data on File, GE Healthcare_Usage
3. Smevik B, Westvik J. Acta Radiol 1990; 31(6): 601-4.
4. Gomi T et al. Eur Radiol 2010; 20(7): 1631-5.
5. Omnipaque Summary of Product Characteristics, July 2016
6. Marshall G. Radiography 2008; 14: 128-34.
7. Gricar J et al. Radiol Manage 2007; SEP/OCT: 34-42.
8. Dhaliwal H et al. Int J Life Cycle Assess 2014; 19: 1965-73
9. Omnipaque Summary of Product Characteristics (UK), September 2018.
  1. WHO Model List of Essential Medicines, 20th List, August 2017
  2. Data on File, GE Healthcare_Usage
  3. Smevik B, Westvik J. Acta Radiol 1990; 31(6): 601-4.
  4. Gomi T et al. Eur Radiol 2010; 20(7): 1631-5.
  5. Omnipaque Summary of Product Characteristics, July 2016
  6. Marshall G. Radiography 2008; 14: 128-34.
  7. Gricar J et al. Radiol Manage 2007; SEP/OCT: 34-42.
  8. Dhaliwal H et al. Int J Life Cycle Assess 2014; 19: 1965-73.